,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04']
the phase 3 destiny-breast04 trial using fam-trastuzumab deruxtecan-nxki showed a reduction in the risk of disease recurrence or death for patients with her2-low, hormone receptor positive metastatic breast cancer. #bcsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.